Fatty acid concentrations, in particular n-3 and n-6 polyunsaturated fatty acids (PUFAs), have been described to be dysregulated in atopic dermatitis (AD) patients. The role of genetic polymorphisms of fatty acid enzymes in AD is controversial. We determined in a Hungarian cohort of healthy volunteers (n = 20) and AD patients (n = 20) triglyceride-, sterol- and phospholipid-bound fatty acids in the plasma, mRNA expression of fatty acid desaturase 2 (FADS2) and stearoyl-coenzyme A desaturase 1 in peripheral blood mononuclear cells (PBMCs) and FADS2 concentrations in plasma. We observed higher levels of monounsaturated fatty acids, 16:1 versus 16:0 ratios in phospholipids, triglycerides and sterol esters in patients compared to healthy subjects. In addition higher levels of the FADS2-derived n-6 PUFAs γ-linolenic acid and dihomo-γ-linolenic acid were observed in PBMCs of patients as well as lower levels of n-3 PUFAs. We conclude that the increased expression of FADS2 in PBMCs, as a representative tissue accessible from human blood of AD patients, might be responsible for higher levels of FADS2-derived n-6 PUFAs and lower n-3 PUFA levels in patients.

Keywords:
Atopic dermatitis, Lipid enzymes, n–3 polyunsaturated fatty acids, n–6 polyunsaturated fatty acids, Fatty acid desaturase 2
1.
Jump DB: The biochemistry of n-3 polyunsaturated fatty acids. J Biol Chem 2002;277:8755-8758.
2.
Drevon CA, Nenseter MS, Brude IR, et al: Omega-3 fatty acids - nutritional aspects. Can J Cardiol 1995;11(suppl G):47G-54G.
3.
Smith WL: Nutritionally essential fatty acids and biologically indispensable cyclooxygenases. Trends Biochem Sci 2008;33:27-37.
4.
Serhan CN, Savill J: Resolution of inflammation: the beginning programs the end. Nat Immunol 2005;6:1191-1197.
5.
Calder PC: Polyunsaturated fatty acids, inflammatory processes and inflammatory bowel diseases. Mol Nutr Food Res 2008;52:885-897.
6.
Kremmyda LS, Vlachava M, Noakes PS, et al: Atopy risk in infants and children in relation to early exposure to fish, oily fish, or long-chain omega-3 fatty acids: a systematic review. Clin Rev Allergy Immunol 2011;41:36-66.
7.
Prescott SL, Calder PC: n-3 polyunsaturated fatty acids and allergic disease. Curr Opin Clin Nutr Metab Care 2004;7:123-129.
8.
Duchen K, Bjorksten B: Polyunsaturated n-3 fatty acids and the development of atopic disease. Lipids 2001;36:1033-1042.
9.
Ziboh VA: The significance of polyunsaturated fatty acids in cutaneous biology. Lipids 1996;31(suppl):S249-S253.
10.
Simopoulos AP: Omega-3 fatty acids in inflammation and autoimmune diseases. J Am Coll Nutr 2002;21:495-505.
11.
Dunstan JA, Mori TA, Barden A, et al: Fish oil supplementation in pregnancy modifies neonatal allergen-specific immune responses and clinical outcomes in infants at high risk of atopy: a randomized, controlled trial. J Allergy Clin Immunol 2003;112:1178-1184.
12.
Koch C, Dolle S, Metzger M, et al: Docosahexaenoic acid (DHA) supplementation in atopic eczema: a randomized, double-blind, controlled trial. Br J Dermatol 2008;158:786-792.
13.
Nagakura T, Matsuda S, Shichijyo K, et al: Dietary supplementation with fish oil rich in omega-3 polyunsaturated fatty acids in children with bronchial asthma. Eur Respir J 2000;16:861-865.
14.
Klemens CM, Berman DR, Mozurkewich EL: The effect of perinatal omega-3 fatty acid supplementation on inflammatory markers and allergic diseases: a systematic review. BJOG 2011;118:916-925.
15.
Woods RK, Thien FC, Abramson MJ: Dietary marine fatty acids (fish oil) for asthma in adults and children. Cochrane Database Syst Rev 2002;3:CD001283.
16.
Berth-Jones J, Graham-Brown RA: Placebo-controlled trial of essential fatty acid supplementation in atopic dermatitis. Lancet 1993;341:1557-1560.
17.
Rackal JM, Vender RB: The treatment of atopic dermatitis and other dermatoses with leukotriene antagonists. Skin Ther Lett 2004;9:1-5.
18.
Lattka E, Illig T, Heinrich J, et al: FADS gene cluster polymorphisms: important modulators of fatty acid levels and their impact on atopic diseases. J Nutrigenet Nutrigenom 2009;2:119-128.
19.
Guillou H, D'Andrea S, Rioux V, et al: The surprising diversity of delta6-desaturase substrates. Biochem Soc Trans 2004;32:86-87.
20.
Zietemann V, Kroger J, Enzenbach C, et al: Genetic variation of the FADS1 FADS2 gene cluster and n-6 PUFA composition in erythrocyte membranes in the European Prospective Investigation into Cancer and Nutrition-Potsdam study. Br J Nutr 2010;104:1748-1759.
21.
Mathias RA, Vergara C, Gao L, et al: FADS genetic variants and omega-6 polyunsaturated fatty acid metabolism in a homogeneous island population. J Lipid Res 2010;51:2766-2774.
22.
Schaeffer L, Gohlke H, Muller M, et al: Common genetic variants of the FADS1 FADS2 gene cluster and their reconstructed haplotypes are associated with the fatty acid composition in phospholipids. Hum Mol Genet 2006;15:1745-1756.
23.
Rzehak P, Thijs C, Standl M, et al: Variants of the FADS1 FADS2 gene cluster, blood levels of polyunsaturated fatty acids and eczema in children within the first 2 years of life. PLoS One 2010;5:e13261.
24.
Miyazaki M, Ntambi JM: Role of stearoyl-coenzyme A desaturase in lipid metabolism. Prostaglandins Leukot Essent Fatty Acids 2003;68:113-121.
25.
Rahman SM, Dobrzyn A, Lee SH, et al: Stearoyl-CoA desaturase 1 deficiency increases insulin signaling and glycogen accumulation in brown adipose tissue. Am J Physiol Endocrinol Metab 2005;288:E381-E387.
26.
Liu X, Strable MS, Ntambi JM: Stearoyl CoA desaturase 1: role in cellular inflammation and stress. Adv Nutr 2011;2:15-22.
27.
Kunz B, Oranje AP, Labreze L, et al: Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis. Dermatology 1997;195:10-19.
28.
Sturzenbaum SR, Kille P: Control genes in quantitative molecular biological techniques: the variability of invariance. Comp Biochem Physiol B Biochem Mol Biol 2001;130:281-289.
29.
Folch J, Lees M, Sloane Stanley GH: A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem 1957;226:497-509.
30.
Buczynski MW, Dumlao DS, Dennis EA: Thematic review series: proteomics. An integrated omics analysis of eicosanoid biology. J Lipid Res 2009;50:1015-1038.
31.
Ntambi JM: Regulation of stearoyl-CoA desaturase by polyunsaturated fatty acids and cholesterol. J Lipid Res 1999;40:1549-1558.
32.
Cao H, Gerhold K, Mayers JR, et al: Identification of a lipokine, a lipid hormone linking adipose tissue to systemic metabolism. Cell 2008;134:933-944.
33.
Miyazaki M, Man WC, Ntambi JM: Targeted disruption of stearoyl-CoA desaturase 1 gene in mice causes atrophy of sebaceous and meibomian glands and depletion of wax esters in the eyelid. J Nutr 2001;131:2260-2268.
34.
Nakamura MT, Nara TY: Structure, function, and dietary regulation of delta6, delta5, and delta9 desaturases. Annu Rev Nutr 2004;24:345-376.
35.
Simopoulos AP: Genetic variants in the metabolism of omega-6 and omega-3 fatty acids: their role in the determination of nutritional requirements and chronic disease risk. Exp Biol Med (Maywood) 2010;235:785-795.
36.
Ge L, Gordon JS, Hsuan C, et al: Identification of the delta-6 desaturase of human sebaceous glands: expression and enzyme activity. J Invest Dermatol 2003;120:707-714.
37.
Zouboulis CC, Angres S, Seltmann H: Regulation of stearoyl-coenzyme A desaturase and fatty acid delta-6 desaturase-2 expression by linoleic acid and arachidonic acid in human sebocytes leads to enhancement of proinflammatory activity but does not affect lipogenesis. Br J Dermatol 2011;165:269-276.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.